Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
AnaptysBio (ANAB) Stock Price & Analysis
316 Followers
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.36 - $27.50
Previous Close$23.94
Volume249.25K
Average Volume (3M)351.44K
Market Cap
$654.01M
Enterprise Value$316.73M
Total Cash (Recent Filing)$354.67M
Total Debt (Recent Filing)$17.39M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 05, 2024EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding27,318,644
10 Day Avg. Volume415,835
30 Day Avg. Volume351,445
Standard Deviation0.21
R-Squared0.00662
Alpha0.00630
Financial Highlights & Ratios
Price to Book (P/B)13.72
Price to Sales (P/S)38.22
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.79
Enterprise Value/Gross Profit18.46
Enterprise Value/Ebitda-2.08
Forecast
1Y Price Target
$49.20Price Target Upside105.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Positive Clinical ResultsThe company shared positive topline Ph3 results for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP).
Strategic Financial MovesManagement amended the Jemperli royalty agreement and will receive an additional $50M.
Strong Pipeline And Future ProspectsThe company's R&D portfolio offers tremendous potential, shares are undervalued, and pipeline newsflow is set to accelerate in late 2024-2025.
Bears Say
Clinical TrialsJNJ evaluated it in a Ph1 RA trial, but JNJ never disclosed those results and did not advance it in RA.
Investor ConcernsSome investors had feared the worst-case scenario that LLY could have dropped it in conjunction with its 1Q results.
UncertaintyWe do not know if LLY will provide any updates on peresolimab in conjunction with 1Q financial results on Apr. 30.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $13.36 and its highest was $27.50 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 05, 2024 which is in 33 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 09, 2024. The company reported -$1.64 earnings per share for the quarter, missing the consensus estimate of -$1.566 by -$0.074.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$0.96.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,318,644 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.64 in its last earnings report, missing expectations of -$1.566. Following the earnings report the stock price went down -10.751%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 11M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.20 (105.51% Upside)
$49.20 (105.51% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 639.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.69%
12-Months-Change
Fundamentals
Return on Equity
-136.73%
Trailing 12-Months
Asset Growth
-26.45%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$49.20
▲(105.51% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+15.00%
assigned a buy rating 12 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +15.00% per trade.
---